Interleukin-6 gene promoter-572 C allele may play a role in rate of disease progression in multiple sclerosis

International Journal of Molecular Sciences

Volumn 13, Issue 10, 2012, Pages 13667-13679

  Yan, Jun ^a   Liu, Jia ^a   Lin, Clement Yihao ^a   Scott, Rodney J ^b,c,d   Brown, Matthew A ^a,e   Booth, David R ^f   Stewart, Graeme J ^f   Broadley, Simon ^g,h   Mason, Deborah ⁱ   Griffiths, Lyn ^g   Moscato, Pablo ^d,j   Slee, Mark ^j   Taylor, Bruce ^k   Wiley, James ^l   Field, Judith ^l   Butzkueven, Helmut ^l,m   Kilpatrick, Trevor J ^l,n   Csurhes, Peter A ^a   Pender, Michael P ^a   McCombe, Pamela A ^a   Greer, Judith M ^a   more..

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b JOHN HUNTER HOSPITAL   (Australia)

^c HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f WESTMEAD HOSPITAL   (Australia)

^g GRIFFITH UNIVERSITY   (Australia)

^h GOLD COAST UNIVERSITY HOSPITAL   (Australia)

ⁱ CANTERBURY DISTRICT HEALTH BOARD   (New Zealand)

^j FLINDERS UNIVERSITY   (Australia)

^k UNIVERSITY OF TASMANIA   (Australia)

^l UNIVERSITY OF MELBOURNE   (Australia)

^m BOX HILL HOSPITAL   (Australia)

ⁿ ROYAL MELBOURNE HOSPITAL   (Australia)

more..

Author keywords

Allele; Disease progression; Genotype; Interleukin 6; Multiple sclerosis; Polymorphism

Indexed keywords

CYSTEINE; INTERLEUKIN 6; HLA ANTIGEN;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HUMAN; INTERLEUKIN 6 GENE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PROMOTER REGION; ADULT; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; METABOLISM; PATHOLOGY; RISK; SEVERITY OF ILLNESS INDEX; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HLA ANTIGENS; HUMANS; INTERLEUKIN-6; MALE; MULTIPLE SCLEROSIS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; SEVERITY OF ILLNESS INDEX;

EID: 84870724340     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms131013667     Document Type: Article

References (23)

1. Pender, MP.; Greer, J.M. Immunology of multiple sclerosis. Curr. Allergy Asthma Rep. 2007, 7, 285-292.
2. Montalban, X. Primary progressive multiple sclerosis. Curr. Opin. Neurol. 2005, 18, 261-266.
3. Ebers, G.C. Natural history of primary progressive multiple sclerosis. Mult. Scler. 2004, 10, S8-S15.
4. McFarland, H.F.; Martin, R. Multiple sclerosis: A complicated picture of autoimmunity. Nat. Immunol. 2007, 8, 913-919.
5. The International Multiple Sclerosis Genetics Consortium. The Wellcome Trust Case Control Consortium Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476, 214-219.
6. Bahlo, M.; Booth, D.R.; Broadley, S.A.; Brown, M.A.; Foote, S.J.; Griffiths, L.R.; Kipatrick, T.J.; Lechner-Scott, J.; Moscato, P.; Perreau, V.M.; et al. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat. Genet. 2009, 41, 824-828.
7. Patsopoulos, N.A.; Bayer Pharma, M.S. Genetics Working Group; Steering Committees of Studies Evaluating IFNf-1b and a CCR1-Antagonist; ANZgene Consortium; GeneMSA; International Multiple Sclerosis Genetics Consortium; Esposito, F.; Reischl, J.; Lehr, S.; Bauer, D.; et al. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann. Neurol. 2011, 70, 897-912.
8. Fedetz, M.; Matesanz, F.; Pascual, M.; Martin, J.; Fernandez, O.; Guerrero, M.; Alcina, A. The -174/-597 promoter polymorphisms in the interleukin-6 gene are not associated with susceptibility to multiple sclerosis. J. Neurol. Sci. 2001, 190, 69-72.
9. Mihailova, S.; Ivanova, M.; Mihaylova, A.; Quin, L.; Mikova, O.; Naumova, E. Pro- and anti-inflammatory cytokine gene polymorphism profiles in Bulgarian multiple sclerosis patients. J. Neuroimmunol. 2005, 168, 138-143.
10. Mirowska-Guzel, D.; Gromadzka, G; Mach, A.; Czlonkowski, A.; Czlonkowska, A. Association of IL1A, IL1B, ILRN, IL6, IL10 and TNF-alpha polymorphisms with risk and clinical course of multiple sclerosis in a Polish population. J. Neuroimmunol. 2011, 236, 87-92.
11. Shahbazi, M.; Ebadi, H.; Fathi, D.; Roshandel, D.; Mohamadhosseni, M.; Tahmasebi, A.; Shahbazi, S.; Zamani, M.; Rashidbaghan, A. HLA-DRB1*1501 intensifies the impact of IL-6 promoter polymorphism on the susceptibility to multiple sclerosis in an Iranian population. Mult. Scler. 2010, 16, 1173-1177.
12. Maimone, D.; Gregory, S.; Arnason, B.G.; Reder, A.T. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J. Neuroimmunol. 1991, 32, 67-74.
13. Stelmasiak, Z.; Koziol-Montewka, M.; Dobosz, B.; Rejdak, K.; Bartosik-Psujek, H.; Mitosek-Szewczyk, K.; Belniak-Legiec, E. Interleukin-6 concentration in serum and cerebrospinal fluid in multiple sclerosis patients. Med. Sci. Monit. 2000, 6, 1104-1108.
14. Ireland, S.J.; Blazek, M.; Harp, C.T.; Greenberg, B.; Frohman, E.M.; Davis, L.S.; Monson, N.L. Antibody-independent B cell effector functions in relapsing remitting multiple sclerosis: Clues to increased inflammatory and reduced regulatory B cell capacity. Autoimmunity 2012, 45, 400-414.
15. Maimone, D.; Guazzi, G.C.; Annunziata, P. IL-6 detection in multiple sclerosis brain. J. Neurol. Sci. 1997, 146, 59-65.
16. Eugster, H.P.; Frei, K.; Kopf, M.; Lassmann, H.; Fontana, A. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur. J. Immunol. 1998, 28, 2178-2187.
17. Fife, M.S.; Ogilvie, E.M.; Kelberman, D.; Samuel, J.; Gutierrez, A.; Humphries, S.E.; Woo, P. Novel IL-6 haplotypes and disease association. Genes Immun. 2005, 6, 367-370.
18. Fishman, D.; Faulds, G.; Jeffery, R.; Mohamed-Ali, V.; Yudkin, J.S.; Humphries, S.; Woo, P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 1998, 102, 1369-1376.
19. Muller-Steinhardt, M.; Fricke, L.; Muller, B.; Ebel, B.; Kirchner, H.; Hartel, C. Cooperative influence of the interleukin-6 promoter polymorphisms -597, -572 and -174 on long-term kidney allograft survival. Am. J. Transpl. 2004, 4, 402-406.
20. Roxburgh, R.H.; Seaman, S.R.; Masterman, T.; Hensiek, A.E.; Sawcer, S.J.; Vukusic, S.; Achiti, I.; Confavreux, C.; Coustans, M.; le Page, E.; et al. Multiple sclerosis severity score: Using disability and disease duration to rate disease severity. Neurology 2005, 64, 1144-1151.
21. Kristiansen, O.P.; Nolsøe, R.L.; Larsen, L.; Gjesing, A.M.P.; Johannesen, J.; Larsen, Z.M.; Lykkesfeldt, A.E.; Karlsen, A.E.; Pociot, F.; Mandrup-Poulsen, T.; DIEGG; DSGD. Association of a functional 17β-estradiol sensitive IL6-174G/C promoter polymorphism with early-onset type 1 diabetes in females. Hum. Mol. Genet. 2003, 12, 1101-1110.
22. Sadovnick, A.D. European Charcot Foundation Lecture: The natural history of multiple sclerosis and gender. J. Neurol. Sci. 2009, 286, 1-5.
23. Polman, C.H.; Reingold, S.C.; Edan, G.; Filippi, M.; Hartung, H.P.; Kappos, L.; Lublin, F.D.; Metz, L.M.; McFarland, H.F.; O'Connor, P.W.; et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 2005, 58, 840-846.